Breaking the silence of RNA interference drugs
A wave of treatments is set to follow the first approval of an RNAi therapy
When it comes to the future of biological medicines, gene therapy has hogged headlines, with the spotlight often falling on Crispr-based gene editing. But in the background, gene silencing using RNA interference has quietly slipped from an academic curiosity to a marketable treatment, with the first RNAi therapy approved in the US this year.
And this is just the start. A bevy of companies are progressing candidates through clinical trials.